CAS: 18880-04-1; 3,4-Dichlorobenzyl Bromide

上下游产品

CAS号95-75-0 3,4-二氯甲苯 | CAS号1805-32-9 3,4-二氯苄醇 | CAS号55513-17-2 1-(3,4-二氯苄基)哌嗪 | CAS号56442-18-3 4-[(3,4-二氯苄基)氧基]苯羧酸 | CAS号3218-49-3 3,4-二氯苯乙腈 | CAS号220772-52-1 1-(3,4-二氯苄基)-4-哌啶酮 | CAS号5807-30-7 3,4-二氯苯乙酸 | CAS号5472-67-3 3,4-二氯苯丙氨酸 | CAS号51-44-5 3,4-二氯苯甲酸 | CAS号328083-79-0 1-(3,4-二氯苄基)-4-... | CAS号19752-09-1 异氰酸3,4-二氯苯甲酯 | CAS号67370-32-5 2-(3,4-Dichloro...

📜3,4-二氯苄醇置于三溴化磷体系中,用 乙醚 用作溶剂,化学反应 0.5H,反应生成3,4-二氯苄溴
参考文献:新型间乙酰氨基酚嵌入 [1,2,3]-三唑衍生物的合成,对接和生物活性
标题:新型间乙酰氨基酚嵌入 [1,2,3]-三唑衍生物的合成,对接和生物活性
摘要:Erα控制乳腺癌的乳腺组织发育和进展.在我们寻找靶向雌激素受体 α 配体结合域的新型化合物时,我们确定了"n-(3-((1H-1,2,3-Triazol-4-yl)Methoxy)Phenyl)乙酰胺"衍生物作为先导化合物. 对接研究表明,当对接至 1Xp6 时,间乙酰氨基酚衍生物的对接得分非常好.已经合成,表征和评估了一系列间乙酰氨基酚衍生物的细胞毒性,抗细菌和抗氧化活性.在测试的 12 种杂化化合物中," 7A,7G,7H和7I"衍生物显示出非常好的细胞毒性,对 Mcf-7 细胞系的ic 50值为 <22 µg/ml.化合物" 7A,7D,7E,7F,7H,7I,7J,7K和7L"显示出出色的抗氧化活性,Ic 50值 < 30 µm,而化合物" 7A,7B,7C,7D,7G,7J,7K和7L"显示中等抗菌活性,Mic 值 <300 µm.
Doi:10.1016/j.Molstruc.2021.130786

专利信息

专利号:US-7189864-B2
优先权日:1990-11-19
标 题:Method of preparing intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

专利号:US-6022996-A
优先权日:1990-11-19
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

专利号:EP-0641333-B1
优先权日:1992-05-20
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO; MONSANTO CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide compound of formula (I) from a chiral alpha amino aldehyde and halomethyllithium as an organometallic methylene-adding reagent. In formula (I) R<1> is selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl and arylalkyl, which are optionally substituted with a group selected from alkyl, halogen, NO2, OR<9> or SR<9>, where R<9> represents hydrogen or alkyl; and P<1> and P<2> independently are selected from amine protecting groups, including but not limited to, arylalkyl, substituted arylalkyl, cycloalkenylalkyl and substituted cycloalkenylalkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl and silyl.

专利号:EP-0855388-B1
优先权日:1993-11-23
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P; FRESKOS JOHN J; DECRESCENZO GARY A; BERTENSHAW DEBORAH E; HEINTZ ROBERT M; ZHANG SUHONG; LIU CHIN; LANEMAN SCOTT A
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a cyanohydrin from a chiral alpha amino aldehyde.

专利号:US-2002161234-A1
优先权日:1990-11-19
标 题 :Method of preparing intermediates useful in synthesis of retroviral protease inhibitors

专利号:US-5872299-A
优先权日:1990-11-19
标 题 :Method of preparing intermediates for retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P; FRESKOS JOHN J; DECRESCENZO GARY A; BERTENSHAW DEBORAH E; HEINTZ ROBERT M; ZHANG SUHONG; LIU CHIN; LANEMAN SCOTT A
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide or cyanohydrin from a chiral alpha amino aldehyde.